Inventor · disambiguated record
Victoria Lynn Wilde
Also filed as: WILDE VICTORIA LYNN
8 granted patents·15 citations·filing 2015–2021
79Inventor score
Files withBETA PHARMA INC8
Top patents by PatentIndex Score
8 records- 0187US9878994B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2015·Granted Jan 30, 2018·8 cites·32 claims
- 0285US10239864B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2018·Granted Mar 26, 2019·5 cites·20 claims
- 0376US10590111B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2015·Granted Mar 17, 2020·2 cites·39 claims
- 0469US12187707B2Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereofBETA PHARMA INC·Filed 2021·Granted Jan 7, 2025·0 cites·13 claims
- 0565US11180478B2Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereofBETA PHARMA INC·Filed 2018·Granted Nov 23, 2021·0 cites·15 claims
- 0661US11414401B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2020·Granted Aug 16, 2022·0 cites·7 claims
- 0759US10844045B2Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereofBETA PHARMA INC·Filed 2017·Granted Nov 24, 2020·0 cites·23 claims
- 0856US11052086B22-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersBETA PHARMA INC·Filed 2017·Granted Jul 6, 2021·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Victoria Lynn Wilde files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →